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Neuraminidase (NA) inhibitors (NAIs) are currently the only class of antiviral drugs recommended by Centers for Disease Control and Prevention (CDC) for the control of influenza infections, due to widespread resistance to the M2 blockers (adamantanes) (Deyde et al., 2007) . In 1999, orally administered oseltamivir and inhaled zanamivir were approved by the United States (U.S.) Food and Drug Administration (FDA) for control of influenza type A and B infections. In December 2014, a third NAI, intravenous peramivir (Shetty and Peek, 2012) , was FDA-approved. Peramivir is also licensed in Japan, South Korea and China, while inhaled laninamivir (Yamashita et al., 2009 ) is approved in Japan. Intravenous zanamivir has been provided for compassionate use in recent years, and is undergoing evaluation for treatment of hospitalized patients with severe influenza (https://clinicaltrials.gov/show/NCT01231620).
During initial post-marketing years, monitoring influenza virus susceptibility to NAIs was carried out by a central laboratory contracted by the Neuraminidase Inhibitor Susceptibility Network (NISN) which utilized chemiluminescence-and fluorescence-based NI assays (Wetherall et al., 2003) . Later, monitoring NAIsusceptibility became an integral part of virological surveillance within the WHO Global Influenza Surveillance and Response System (WHO-GISRS), where both functional (NA inhibition) and sequence-based (pyrosequencing, real time RT-PCR, Sanger) assays have been utilized to conduct drug susceptibility monitoring worldwide (Monto et al., 2006; Meijer et al., 2014) . Following the FDA's approval of zanamivir and oseltamivir, CDC implemented the NI assay, first using a chemiluminescence-based (Mungall et al., 2004) , then a fluorescence-based methodology (OkomoAdhiambo et al., 2013) . The NI assay testing is done for the purpose of monitoring changes in the baseline NAI susceptibility of circulating influenza viruses.
Historically, there has been significant variability in IC 50 data (the drug concentration required to inhibit 50% of viral NA enzyme activity), due to factors such as variations in assay choice and/or assay conditions. The lack of standardization in NI assay methodologies and the resulting IC 50 variability has been a challenge in sharing and interpreting IC 50 data among laboratories. In 2012, in efforts to harmonize the interpretation and reporting of IC 50 data, the WHO Expert Working Group for GISRS on Surveillance of Antiviral Susceptibility (WHO-AVWG) agreed on criteria to define influenza viruses as exhibiting normal, reduced (RI) or highly reduced (HRI) NA inhibition, based on the fold change of their IC 50 compared to reference IC 50 values (WHO, 2012) . These criteria have been helpful in interpretation and reporting of NI assay data generated by different WHO Collaborating Centers (OkomoAdhiambo et al., 2014; Takashita et al., 2014 Takashita et al., , 2015a , and for providing annual global updates (Meijer et al., 2014; Takashita et al., 2015b) . Viruses of N1 subtype carrying the H275Y substitution in the NA (H274Y in N2 subtype) and A(H3N2) viruses carrying E119V or R292K substitutions consistently demonstrate HRI by oseltamivir in NI assays (Meijer et al., 2014; Okomo-Adhiambo et al., 2014; Takashita et al., 2015b) .
In the summer of 2011, the CDC spearheaded efforts to standardize influenza NI testing within the U.S., in collaboration with the Association for Public Health Laboratories (APHL) and several state public health laboratories (PHLs), with the goal of minimizing NI assay IC 50 data variability within and among surveillance laboratories, as well as increasing the US capacity to monitor the NAI susceptibility of influenza viruses. Three PHLs, designated as National Surveillance Reference Centers for Influenza (NSRC-Is), namely, the California Department of Public Health (CDPH), Richmond, CA; Unified State Laboratories, Public Health (USLPH), Taylorsville, UT; and the Wisconsin State Laboratory of Hygiene (WSLH), Madison, WI, participated in the "Project for Standardization of NAI Susceptibility Testing," through a step-wise procedure developed by the CDC. In April 2012, Maryland Department of Health and Mental Hygiene (MD DHMH) Laboratories Administration also participated in an additional NI Standardization Project, but was not selected as a NSRC-I.
After successfully completing the standardization process, the three NSRC-Is performed NI assay testing on U.S. influenza surveillance specimens collected during the 2011e12 season, and three subsequent seasons, 2012e13, 2013e14, and 2014e15. The NI assay testing activity was added to an ongoing APHL contract for influenza virus isolation, collectively referred to as the "VI/NI Project." At CDC, standardized IC 50 data generated by the NSRC-Is were further analyzed based on criteria of the WHO-AVWG (WHO, 2012) to identify viruses with RI or HRI, which were genetically analyzed by pyrosequencing and/or conventional NA sequence analysis to determine underlying NA changes responsible for elevated IC 50 s. Viruses with markers previously associated with resistance to NAI(s) were reported as NAI-resistant to the WHO GISRS and in the U.S. influenza virological surveillance Report (FluView) (http://www.cdc.gov/flu/weekly/).
This report describes results of the NI assay standardization project performed on the 2011e12 CDC reference virus panel by three NSRC-Is (CDPH, USLPH and WSLH), as well as NI assay data for U.S. influenza surveillance isolates they tested during seasons 2011e15. These results suggest that NAI drug susceptibility data generated in the NI assay can be interpreted and shared in a consistent, reproducible manner when detailed procedures and reference materials are used in assay implementation.
Materials and methods

Training
Prior to the standardization process, participating laboratories received training on the fluorescent NI assay by CDC laboratorians, through lectures and hands-on instruction. The training course, conducted in April 2011, was sponsored by the APHL, CDC and National Laboratory Training Network (NLTN), and comprised preand post-test knowledge assessment; background information on influenza and drug susceptibility testing; NI assay workflow; reagent and drug preparation; determination of virus dilutions for use in the NI assay; identification of acceptable NI assay results; equipment operation; IC 50 data analysis and interpretation.
Viruses
The 2011e12 CDC reference panel ( 
Neuraminidase inhibitors
Oseltamivir carboxylate, the active compound of the ethyl ester prodrug oseltamivir phosphate was kindly provided by HoffmannLa Roche (Basel, Switzerland), zanamivir by GlaxoSmithKline (Uxbridge, UK), and peramivir by BioCryst Pharmaceuticals (Birmingham, AL). Note, oseltamivir, zanamivir and peramivir are also available commercially (Sequoia Research Products, Pangbourne, United Kingdom). In this study, NAIs (in powder form) were obtained from respective manufacturers through material transfer agreements (MTAs), then weighed and reconstituted using deionized distilled water (to 20 mM solutions), according to procedures described in the CDC fluorescent NI assay protocol. These 20 mM solutions were then diluted into 50 mM stock solutions, which were used to prepare 3.16-fold (half-log 10 ) serial dilutions of NAIs (total of 10), starting from 4 mM (4000 nM) to a final concentration of 0.12 nM.
Neuraminidase inhibition assay
Virus susceptibility to NAIs was assessed in the fluorescent NI assay that utilizes 2-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid (MUNANA) as substrate. The assay was performed using the NA-Fluor™ Influenza Neuraminidase Assay Kit (Applied Biosystems/Life Technologies, Carlsbad, CA) in 96-well opaque black flat-bottom microplates (Corning Inc., Corning, NY), according to the CDC protocol, which can be requested by email (fluantiviral@cdc.gov). The CDC fluorescent NI assay protocol is optimized to the needs of virological surveillance (OkomoAdhiambo et al., 2013) and somewhat differs from the manufacturer's instructions in the NA-Fluor™ kit manual. Briefly, viruses were diluted at concentrations corresponding to the target fluorescence signal generated by 1000 pmol/well of 4-methylumbelliferone (4-MU) standard. A virus dilution calculation spreadsheet (Excel, Microsoft, Redmond, WA) was used to determine the appropriate dilution of virus to be used in the inhibition portion of the assay. This tool rapidly provides the dilutions of virus, together with the volumes of virus and 1Â NA-Fluor™ Assay Buffer to be used. Subsequently, 25 mL of each diluted virus was mixed with 25 mL of a range of concentrations of each NAI (0.12 nMe4000 nM; with a final concentration in the reaction of 0.03 nMe1000 nM) and incubated at 37 C for 45 min, after which 50 mL of the 200 mM NA-Fluor™ Substrate (MUNANA) was added to the virus and inhibitor mix, and incubated at 37 C for 60 min. The reaction was terminated with 100 mL NA-Fluor™ Stop Solution.
Fluorescence was detected on the Victor 3 V™ (USLPH), Victor X4™
(WSLH) or Victor X2™ (CDPH) plate reader (PerkinElmer, Shelton, CT), equipped with filters for excitation (l ¼ 365 nm) and emission (l ¼ 450 nm). Note, the CDC currently uses the BioTek™ plate reader platform, models Synergy H1™, Synergy Neo™ and Cytation 3™ (BioTek Instruments Inc., Winooski, VT).
Resources provided by CDC
Participating laboratories (NSRC-Is) were provided with a detailed standard operating procedure (SOP) for the fluorescent NI assay utilizing the NA-Fluor™ Influenza Neuraminidase Assay Kit (Okomo-Adhiambo et al., 2013) . Besides the SOP, the CDC also provided materials and tools, including a virus dilution calculator tool; JASPR v1.2 curve-fitting software (CDC, Atlanta, GA); the 2011e12 CDC reference virus panel; aliquots of verified 50 mM NAI stock solutions (for the first phase of the study); and technical support for troubleshooting. Additionally, CDC laboratorians conducted site visits to monitor NI assay implementation for the impending 2011e12 influenza season.
Testing algorithm for NI assay standardization
In the first phase of the standardization process, participating laboratories (NSRC-Is) performed the NI assay on 2011e12 CDC reference panel viruses grown by CDC (n ¼ 8), using NAIs that the CDC obtained, weighed, reconstituted and diluted. The laboratories were provided with 50 mM NAI stock solutions which they diluted to the final concentrations (0.12e4000 nM) required for NI assay testing. For the second phase, participating laboratories prepared their own stocks of the 2011e12 CDC reference panel viruses, and tested them with NAIs they obtained from manufacturers in powder form, and weighed, reconstituted and diluted in-house. Commonly, each NI assay test was replicated at least twice. After successfully completing the NI assay standardization process, the NSRC-Is tested U.S. influenza A and B surveillance isolates collected during the 2011e12 season (n ¼ 940), using NAIs obtained and prepared in-house. A subset (n ¼ 742) of these viruses were tested in parallel by the CDC. The 2011e12 CDC reference panel influenza A(H1N1)pdm09 viruses, A/California/07/2009 wildtype and A/ North Carolina/39/2009 H257Y, were included in each NI assay test as controls. Note, the tested surveillance isolates were propagated by NSRC-Is as part of the VI/NI project or by CDC (viruses submitted to CDC directly), and NAIs were prepared by each NSRC-I and the CDC, respectively. Subsequently, the NSRC-Is tested surveillance isolates (n ¼ 6773) circulating during the 2012e15 influenza seasons; the A(H1N1)pdm09 viruses, A/California/12/2012 wildtype and A/Texas/23/2012 H275Y, from CDC reference virus panel version 2, were included in each NI assay test for quality control. All NI assay data generated by the NSRC-Is were submitted to the CDC for evaluation via secure file transfer protocol (FTP).
Data analysis
Fifty percent inhibitory concentration (IC 50 ) values were determined using JASPR v1.2 curve-fitting software (CDC, Atlanta, GA) by participating laboratories. The CDC laboratory performed statistical analyses of IC 50 values using SAS v9.3 (SAS Institute, Cary, NC), with statistical significance set at a ¼ 0.05. One-way analysis of variance (ANOVA) was used to compare means of IC 50 s generated for the 2011e12 reference virus panel tested for the standardization process, while non-parametric ANOVA (Pappas and DePuy, 2004 ) was used to compare medians of IC 50 s for the 2011e15 U.S. surveillance isolates.
Sequence analysis
To identify known and/or novel markers associated with elevated IC 50 , viral RNA was extracted from isolates and NA sequence analyzed by pyrosequencing (Deyde and Gubareva, 2009) and/or Sanger sequencing (Sheu et al., 2008) . Amino acid substitutions are named according to specific influenza A NA subtype or B type sequence numbering (straight numbering).
Results
The NI assay standardization process was conducted on the 2011e12 CDC reference virus panel (Table 1 ) comprising four pairs of wildtype virus and NA variants with known molecular markers previously associated with elevated IC 50 s for one or more NAIs, covering a wide range of IC 50 values. The three participating laboratories designated as NSRC-Is (CDPH, USLPH, and WSLH), first tested the 2011e12 CDC reference virus panel propagated by CDC, using NAIs obtained and prepared by the CDC (the laboratories were provided with 50 mM stock solutions which they diluted further). This was followed by testing of the same reference virus panel propagated by each participating laboratory, and using NAIs they obtained and prepared in-house (Table 2) . The IC 50 s generated for CDC-propagated viruses with CDCprepared NAIs (Table 2) 20 nM) . Similarly, the peramivir IC 50 for A/Washington/01/2007(H3N2) wildtype virus generated by WSLH (0.14 nM) was 2-3-fold higher compared to those of CDPH (0.06 nM) and USLPH (0.05 nM). These differences were not statistically significant (p > 0.05). Using viruses they propagated and NAIs prepared in-house, the participating laboratories were able to successfully reproduce the IC 50 s they generated using the viruses and NAIs prepared by the CDC (p-values comparing IC 50 s derived from the two scenarios were insignificant, range 0.073e0.980). These IC 50 s also exhibited minimal inter-assay and inter-laboratory variation, although those generated by USLPH tended to be lower ( 2-fold) compared to those of CDPH and WSLH. However, these differences were generally <2-fold and were not significant at the assessed level of confidence (p > 0.05). Overall, the IC 50 s for the 2011e12 reference virus panel generated by the three laboratories for the standardization process, were comparable to those generated by the CDC for the same reference virus panel (Table 1) , and were within the ranges expected for wildtype and NA variant virus pairs of the four influenza type/subtypes that were assessed.
Upon completion of testing the 2011e12 CDC reference virus panel for the standardization process, and implementing the NI assay, the three NSRC-Is (CDPH, USLPH and WSLH) performed the NI assay on 2011e12 U.S. influenza surveillance specimens (Table 3) , in efforts to strengthen domestic influenza virological surveillance. A total of 940 virus isolates were tested by the NSRCIs, of which 742 (80%) were tested in parallel by CDC for data quality purposes, and to enable testing of virus susceptibility to investigational laninamivir (data not shown). Within individual laboratories, there was minimal inter-assay variation in IC 50 s for the respective NAIs and virus type/subtypes (Table 3) . Inter-laboratory variation in IC 50 s was also minimal, with few exceptions that were not statistically significant (p > 0.05). For example, the mean oseltamivir IC 50 for A(H1N1)pdm09 viruses generated by WSLH (0.12 nM) was~2-fold lower than that for CDPH (0.19 nM) and only slightly less than for USLPH (0.16 nM). Similarly, the mean peramivir IC 50 for B viruses generated by WSLH (0.27 nM) was~2-fold lower than those for CDPH (0.49 nM) and USLPH (0.54 nM). Overall, the IC 50 s for respective NAIs and virus type/subtypes generated by the NSRC-Is, were consistent and comparable with those generated by the CDC for the same set of viruses (Table 3) Following successful NI assay testing in season 2011e12, the three NSRC-Is continued testing U.S. surveillance isolates (n ¼ 6773) circulating during the 2012e13 (n ¼ 2114), 2013e14 (n ¼ 2756) and 2014e15 (n ¼ 1903) influenza seasons. During these three seasons, as well as the previous 2011e12 season, the NSRC-Is assessed virus susceptibility to three NAIs, oseltamivir, zanamivir and peramivir, but in 2012e13 they did not monitor peramivir susceptibility. Median IC 50 s for oseltamivir, zanamivir and peramivir generated by the NSRC-Is during four influenza seasons (2011e15) were generally uniform within individual laboratories from season to season (Fig. 1) , although a few exceptions were noted. Within WSLH, the median IC 50 for peramivir among influenza A(H1N1)pdm09 viruses in 2011e12 (0.03 nM) was~2-fold lower compared to seasons 2013e14 (0.05 nM) and 2014e15 (0.06 nM). Among the NSRC-Is, median IC 50 s for respective NAIs and virus type/subtypes were consistent during 2011e2015, with few exceptions, such as the 2014e15 median IC 50 of oseltamivir among influenza B generated by CDPH (10.54 nM), which varied by almost 2-fold compared to USLPH (4.99 nM) and was slightly higher than that for WSLH (7.15 nM). Overall, the median IC 50 s obtained by the NSRC-Is over four seasons (2011e15), for respective NAIs and virus type/subtypes, were consistent with those generated by CDC (Supplemental Table S2 ), and differences if any were 2-fold and not statistically significant (p < 0.05). The standardization process significantly increased capabilities for the NI assay in the U.S., with NSRC-Is accounting for~80% of all NI testing performed on U.S. surveillance isolates circulating during the 2012e13, 2013e14 and 2014e15 influenza seasons. Standardizing the NI assay is, however, not practical for laboratories involved in monitoring influenza antiviral susceptibility globally. To address this issue, WHO-AVWG developed a set of criteria for reporting NI assay results based on IC 50 fold change difference compared to a reference such as the median IC 50 for the respective NAI and virus type (WHO, 2012) . During seasons 2012e15, these criteria were applied to identify viruses with fold differences above a respective median IC 50 value for the same NAI and type/subtype; viruses exhibiting RI or HRI were re-tested in the NI assay by NSRC-Is for the result confirmation and submitted to CDC for comprehensive characterization. In some instances, epidemiological investigations were initiated by the CDC (Okomo-Adhiambo et al., 2015; Garg et al., 2013) .
The introduction of the WHO-AVWG criteria (WHO, 2012) allowed an expanded scope of the original project. Two state PHLs that were not part of the primary CDC/APHL standardization project, MD DHMH, and the New York State Department of Health (NYDOH), also conducted NI testing using the NA-Fluor™ Influenza Neuraminidase Assay Kit, according to their in-house protocols. The generated IC 50 values were interpreted in accord with the WHO-AVWG classification criteria. During the 2014e15 season, the MD DHMH laboratory tested a total of 329 influenza A(H3N2) (n ¼ 253) and B (n ¼ 76) viruses collected in the state of Maryland between Oct 01, 2014 and May 17, 2015. All viruses exhibited normal inhibition by oseltamivir, zanamivir and peramivir, with exception of one (0.4%) A(H3N2) virus with RI by zanamivir (15-fold increase in IC 50 compared to the median IC 50 for the subtype). This virus and its original clinical specimen were submitted to CDC for further Table 3 Fluorescent NI assay IC 50 s for season 2011e12 U.S. influenza A and B surveillance isolates, tested in parallel by the NSRC-Is and CDC (n ¼ 742).
NAI
Influenza type/Subtype Mean IC 50 characterization. Full NA sequence analysis of the virus isolate detected the cell culture adaptive Q136K substitution, which was absent in the matching clinical specimen. The NYDOH laboratory tested a total of 95 influenza A(H3N2) (n ¼ 78) and B (n ¼ 17) viruses collected in New York state between Jan 16 and May 01, 2015; all viruses exhibited normal inhibition by oseltamivir and zanamivir (peramivir was not assessed). Overall, standardized NI assay procedure with three FDAapproved NAIs, conducted by four laboratories (CDC and three NSRC-Is) (n ¼ 3015), as well as harmonization of reporting from two additional laboratories (MD DHMH and NYDOH) (n ¼ 424), resulted in a total of 3439 circulating U.S. influenza viruses tested during the 2014e15 season (Oct 01, 2014 to Jun 23, 2015 , including 68 A(H1N1)pdm09, 2174 A(H3N2) and 1197 B viruses. Only two (0.1%) U.S. viruses with molecular markers of NAI resistance were detected, including one A(H1N1)pdm09 virus with H275Y and one A(H3N2) virus with E119V NA substitutions.
Discussion
Biochemical NI assays have been the cornerstone of NAI susceptibility monitoring programs. They provide a valuable means to screen virus isolates to identify those with elevated IC 50 s which can indicate potential NAI resistance. Coupled with genetic analysis, the NI assay is especially valuable when information on drug resistance markers is not available or sparse, such as when a new NAI is marketed or a novel virus emerges . The IC 50 values generated in NI assays also provide information for comparison of inhibitory effects of different NAIs thus aiding in identification of cross-resistant viruses. Variations in IC 50 values determined for the same virus and drug can arise from sources such as use of different enzyme substrates (fluorescent vs chemiluminescent), buffer systems, time of incubation, and other assay conditions (Nguyen et al., 2010; McKimm-Breschkin et al., 2003; McKimm-Breschkin and Barrett, 2014; Tisdale, 2000) . The goal of the standardization process was to achieve consistency of IC 50 data across participating laboratories through the application of uniform NI assay testing procedures (same kit and assay protocol) with support from the CDC reference laboratory. In this study, critical factors including the use of a standardized SOP, commercial NI assay kit, and the CDC reference virus panel, enabled the generation of reproducible results among laboratories participating in the NI assay standardization process. Although participating laboratories and the CDC reference laboratory utilized different plate reader models, all were equipped with standard filters for excitation (l ¼ 365 nm) and emission (l ¼ 450 nm), set to measure fluorescence for 0.1 s. All plate readers were calibrated prior to their initial use by running 4-methylumbelliferone (4-MU) standards to verify optimal plate reader settings and to determine fluorescent signal targeted for virus working dilution. Viruses were diluted at concentrations corresponding to the target fluorescence signal generated by 1000 pmol/well of 4-methylumbelliferone (4-MU) standard. This procedure was repeated whenever major repair or recalibration was done to a plate reader. There were no apparent variations in IC 50 s attributable to differences in plate reader models.
The commercially available NA-Fluor™ Influenza Neuraminidase Assay Kit used in this study provides the necessary assay reagents, but it lacks NAIs and plates. It also does not include reference material such as influenza viruses exhibiting a range of IC 50 values. Preparation of NAI and virus dilutions may vary by laboratory, potentially resulting in IC 50 variability. CDC provided the NAI preparations to see if there were any differences in IC 50 s for the viruses tested using CDC-prepared drug compared to testing done with NAIs prepared in-house. Preparation of NAIs from their original powder form to concentrations required for the NI assay involves several steps, in which errors may be introduced. In this study, the Tocris Molarity Calculator (http://www.tocris.com/ molarityCalculator.php) was used to determine appropriate volumes of water for initial reconstitution of drugs from powder form. Caution was taken during pipetting to ensure accurate volumes of water were dispensed when diluting NAIs. Laboratories participating in the standardization project were advised to test newly prepared NAIs in parallel to old drug preparations, to confirm accuracy in reconstitution and dilution, and ensure consistency. Although beyond the scope of this study, surveillance laboratories could explore the option of requesting analytically pre-weighed NAIs upon placing a purchase order to commercial entities that offer zanamivir, oseltamivir carboxylate, and peramivir.
In this study, there was no evidence of IC 50 variability arising from drug preparation or viruses; differences in IC 50 s derived using CDC-versus PHL-prepared drug were minimal (<2-fold) within individual laboratories and also between the laboratories. Two-fold differences in IC 50 s have been observed among personnel in the same laboratory. The present study also showed no significant variations in IC 50 s arising from virus propagation. Nevertheless, participating laboratories were advised by the CDC to limit the number of virus passages since it could lead to emergence of NA changes resulting in elevated IC 50 s (Tamura et al., 2013; Mishin et al., 2014) .
The success of the NI assay standardization project affirmed that NAI susceptibility data generated in the NI assay could be shared and interpreted in a consistent, reproducible manner. The success of this project can be attributed to several factors including good laboratory practices; the participating laboratories have standard practices of annual pipette calibration, as well as maintenance and performance monitoring of equipment, including plate readers and incubators. The set of tools developed by CDC and shared with the three NSRC-Is, including the fluorescent NI assay SOP, virus dilution calculator, software for IC 50 calculation, seeds to propagate inhouse reference virus stocks, as well as other support and guidance, were essential for the success of this project. Hands-on training of personnel new to NI testing is also desirable, as is maintaining optimized protocols, as well as necessary reagents, reference viruses and NAI drug stocks. To sustain the quality of future NI assay testing, prior to each upcoming influenza season, laboratories should test reference panels such as CDC or ISIRV-AVG (http://www.isirv.org/site/index.php/reference-panel). Ideally, elements of the NI assay including laboratory infrastructure, protocols, technology, and reagents should be standardized in laboratories in the U.S. and across the globe. However, many laboratories, especially those in resource-poor countries, lack the infrastructure and means necessary to develop, validate, and comply with requirements for NI assay standardization.
The successful implementation of NI testing on season 2011e12 surveillance isolates, and subsequent testing of viruses collected during seasons 2012e15 by the NSRC-Is, proved the effectiveness of the NI assay standardization and expansion efforts which spanned 5 years, and was instrumental in increasing U.S. domestic influenza antiviral surveillance capabilities and pandemic preparedness. This project marks the first time that IC 50 data have been standardized across multiple laboratories performing influenza antiviral susceptibility testing, and incorporated into the U.S. national virological surveillance. The successful NI assay standardization process will enable the expansion of the number of surveillance laboratories capable of drug susceptibility testing both nationally and internationally, assessment of virus susceptibility to new NAIs and testing of novel viruses. These efforts are expected to significantly impact monitoring of influenza antiviral resistance, and will ensure accurate, timely information for public health surveillance.
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